MEDICAMEQ · Medicamen Biotech Ltd · Biotechnology & Drugs
MEDICAMEQ · Medicamen Biotech Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
38.4% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹48 Cr
Revenue YoY
PAT YoY
-1.4%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
1.6
P/S (TTM)
2.2
Sector P/E
36.3
Dividend yield
+0.3%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| MEDICAMEQ (this stock) | 28.8 | 1.6 | +5.0% | +3.7% | 0.17 | +0.3% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
stable
MF
Not available from data source
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 30 Sept 2026 | Sanjay Bansal | SELL | 32,813 | ₹1.05 Cr |
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedMedicamen Biotech Limited (MEDICAMEQ) reported a final dividend of 10% for FY2024-25, with a payment date of October 25, 2025, subject to tax at source. The company's market capitalization stood at ₹612.46 crores on BSE and ₹608.52 crores on NSE as of March 31, 2025. The Board emphasized a strategic shift towards product development and partnerships with global entities, signaling growth. The company has no defaults under the Insolvency and Bankruptcy Code, 2016, and no penalties or strictures were imposed during the year. Internal controls were found adequate, with no material weaknesses identified. The company has adopted governance guidelines and a Business Responsibility Policy, and its auditors provided an unmodified opinion on financial statements and internal controls. The company has not defaulted on loans or borrowings, and no litigation is pending that would impact its financial position. The auditor's report noted no key audit matters, and the consolidated financial statements were audited without material issues. The company has a robust compliance framework, including data privacy and cybersecurity measures, and has implemented a whistleblower policy. The company's financial statements show no material contingent liabilities, and the auditor did not note any going-concern uncertainties. The company has a strong corporate governance structure, with all statutory requirements and SEBI regulations complied with. The company's financial position appears stable, with no significant risks or defaults reported.
- Final dividend of 10% declared for FY2024-25, payable by October 25, 2025.
- Market capitalization of ₹612.46 crores on BSE and ₹608.52 crores on NSE as of March 31, 2025.
- No defaults under the Insolvency and Bankruptcy Code, 2016, and no penalties or strictures imposed.
- Internal controls were found adequate with no material weaknesses identified.
- No pending litigation that would impact financial position.
Key takeaway: Medicamen Biotech Limited reported a stable financial position with no defaults, adequate internal controls, and no material risks, supported by an unmodified auditor's opinion and compliance with regulatory requirements.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Regulatory Action (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Regulatory Action
1 occurrenceRecent (last 12 months)
The company was fined ₹7,080 by NSE for delayed submission of shareholding pattern report and ₹1,10,920 by BSE and NSE for non-compliance with the constitution of the Nomination and Remuneration Committee.
Routine disclosures
Contingent Liability
3 occurrencesRecent (last 12 months)
The company has contingent liabilities not provided for, including import letter of credit USD 1,60,812 (INR 148.53 lakh), inland letter of credit INR 87.85 lakh, foreign guarantee USD 4,25,990 (INR 403.99 lakh), and inland guarantee INR 5.00 lakh as of 31 March 2026.
Earlier (1-3 years ago)
The company has contingent liabilities not provided for, including import letter of credit USD 45,854.50 (equivalent to ₹38.98 lakh), inland letter of credit ₹66.96 lakh, and foreign guarantee USD 63,642.00 (equivalent to ₹55.50 lakh) as of March 31, 2025.
The company has contingent liabilities not provided for, including import letter of credit USD NIL (previous year USD 518,250), inland letter of credit ₹469.70 lakh, foreign guarantee USD 1,85,011.00, and inland guarantee ₹23.50 lakh as of March 31, 2024.
Related-Party Transaction
1 occurrenceRecent (last 12 months)
The company approved material related party transactions with Medicamen Life Sciences Private Limited, a subsidiary company.
Management & Board Governance
2 occurrencesRecent (last 12 months)
Medicamen Biotech Limited's Corporate Governance Reports submitted to stock exchanges (BSE and NSE) contained inaccuracies in attendance, quorum, and related particulars when cross-referenced with the Minutes of Board and Committee Meetings held during 2025-26.
Earlier (1-3 years ago)
The company did not comply with SEBI Regulation 26A (2) by not appointing a new CFO within three months of Mr. Pratap Singh Rawat's resignation on August 14, 2024, as Mr. Chandan Kumar was appointed on February 11, 2025.